Skip to main content

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity.
Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed.
To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms.
To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution.
Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Net EU contribution
€ 243 352,80
Address
Hansastrasse 27C
80686 Munchen
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

MCMASTER UNIVERSITY
Canada
Net EU contribution
€ 0,00
Address
1280 Main St West
L8S 4L8 Hamilton

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 157 622,40